Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2019 09:09 ET | Source: Kitov Pharma Ltd.

Kitov to Acquire Clinical Stage Candidate CM-24 Creating a Transformational Immuno-Oncology Company

- Transaction adds immune oncology candidate to Kitov’s pipeline which includes promising NT-219 cancer drug resistance prevention therapeutic candidate - Kitov to receive $3.5M investment from...
February 07, 2019 08:06 ET | Source: Kitov Pharma Ltd.

Kitov Pharma Reports Year End 2018 Financial Results and Provides Business Update

TEL AVIV, Israel, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today reported its unaudited financial results for the year ended December...
January 18, 2019 16:30 ET | Source: Kitov Pharma Ltd.

Kitov Closes $6 Million Registered Direct Offering

TEL-AVIV, Israel, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced the closing of its previously announced registered...
January 16, 2019 13:35 ET | Source: Kitov Pharma Ltd.

Kitov Announces Pricing of $6 Million Registered Direct Offering

TEL-AVIV, Israel , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that it has entered into definitive agreements...
January 15, 2019 08:41 ET | Source: Kitov Pharma Ltd.

New Data on Kitov’s NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer Effect

NT219 is a first-in-class drug candidate with high affinity and selectivity to its target proteinsData show that even a short exposure of cancerous cells to NT219 was sufficient to trigger...
January 03, 2019 07:19 ET | Source: Kitov Pharma Ltd.

Kitov Signs Marketing and Distribution Agreement for its Lead Product Consensi™ in the U.S. with Coeptis Pharmaceuticals

- Kitov to receive $3.5M milestone payments and 40% - 60% of net profit on sales of Consensi ™- Coeptis to cover all CMC, sales, and marketing expenses TEL AVIV, Israel, Jan. 03, 2019 (GLOBE...
October 11, 2018 08:26 ET | Source: Kitov Pharma Ltd.

Kitov Appoints Gil Efron as Deputy Chief Executive Officer and Chief Financial Officer

Simcha Rock to Retire as CFO and Remain on Kitov’s Board of Directors TEL AVIV, Israel, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma (NASDAQ/TASE: KTOV), an innovative biopharmaceutical...
September 26, 2018 09:40 ET | Source: Kitov Pharma Ltd.

Kitov to Present Data on NT219 in Combination with Keytruda® and Erbitux® at AACR International Cancer Immunotherapy Conference

Treatment with NT219 in combination with Keytruda® or Erbitux® converted non-responding tumors to responders TEL AVIV, Israel, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma (NASDAQ/TASE:...
September 18, 2018 12:57 ET | Source: Kitov Pharma Ltd.

Kitov Pharma Updates on Motions in USA Initiated by Kitov Chairman

Tel Aviv, Israel, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that, following a filing by Kitov’s Chairman of...
August 29, 2018 08:00 ET | Source: Kitov Pharma Ltd.

Kitov Pharma Provides Corporate Update and Reports First Half 2018 Financial Results

Tel Aviv, Israel, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today provided a corporate update and reported financial results...